论文部分内容阅读
目的 :研究抑癌基因P16蛋白在前列腺癌及癌旁非典型增生组织中的表达。方法 :采用免疫组织化学S -P法 ,对 4 0例前列腺癌及 30例前列腺癌旁非典型增生组织进行P16蛋白的免疫组化检测。结果 :4 0例前列腺癌中有18例为阳性反应 (45 % ) ,其中高分化癌阳性率为 6 7% (4/ 6 ) ,中分化癌为 4 5 % (10 / 2 2 ) ,低分化癌为 33% (4/ 12 )。 30例前列腺癌旁非典型增生组织中有 2 1例呈阳性反应 (70 % )。P16蛋白在前列腺癌中的表达阳性率低于癌旁非典型增生组织 (p <0 .0 5 )。结论 :P16蛋白在前列腺癌中的表达阳性率随着前列腺癌病理分级和恶性程度的增加显著降低 ,P16蛋白参与前列腺癌的发生、发展 ,可作为前列腺癌生物学行为及预后评估的参考指标之一。
Objective: To study the expression of tumor suppressor gene P16 in prostate cancer and adjacent non-canonical hyperplasia tissues. Methods: Immunohistochemical S-P method was used to detect the expression of P16 protein in 40 cases of prostate cancer and 30 cases of atypical hyperplasia of prostate cancer. RESULTS: Eighteen of 40 cases of prostate cancer were positive (45%). The positive rate of well differentiated carcinoma was 67% (4/6) and that of moderately differentiated carcinoma was 45% (10/22) Differentiated cancer was 33% (4/12). Twenty-one cases of atypical hyperplasia of prostate cancer showed a positive response (70%). The positive rate of P16 protein expression in prostate cancer was lower than that in atypical hyperplasia (p <0.05). Conclusion: The positive rate of P16 protein in prostate cancer is significantly decreased with the increase of pathological grade and malignant degree of prostate cancer. P16 protein is involved in the occurrence and development of prostate cancer and may serve as a reference index for evaluating the biological behavior and prognosis of prostate cancer one.